Dogwood Therapeutics, Inc. - Common Stock, $0.0001 par value (DWTX)

CUSIP: 92829J203

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class
Equity / Common Stock, $0.0001 par value
Shares outstanding
29,716,833
Total 13F shares
43,200
Share change
-38,769
Total reported value
$207,544
Price per share
$4.77
Number of holders
10
Value change
-$197,053
Number of buys
3
Number of sells
7

Quarterly Holders Quick Answers

What is CUSIP 92829J203?
CUSIP 92829J203 identifies DWTX - Dogwood Therapeutics, Inc. - Common Stock, $0.0001 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of DWTX - Dogwood Therapeutics, Inc. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
William Pridgen
3/4/5
Director
mixed-class rows
764,196
mixed-class rows
$992,479 26 Feb 2024
Orca Capital AG
13D/G
3.7%
69,821
$390,299 -$256,967 14 Mar 2025
UBS Group AG
13F
Company
0.1%
29,818
$149,389 31 Mar 2025
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.05%
14,409
$72,195 31 Mar 2025
13F
FNY Investment Advisers, LLC
13F
Company
0.04%
12,500
$62,000 31 Mar 2025
13F
VANGUARD GROUP INC
13F
Company
0.04%
11,782
$59,028 31 Mar 2025
13F
HRT FINANCIAL LP
13F
Company
0.04%
11,228
$56,000 31 Mar 2025
13F
Tower Research Capital LLC (TRC)
13F
Company
0%
1,050
$5,260 31 Mar 2025
13F
MORGAN STANLEY
13F
Company
0%
600
$3,006 31 Mar 2025
13F
CK Life Sciences Intl (Holdings) Inc
3/4/5
Director, Other*, 10%+ Owner
class O/S missing
284
$1,993 12 Mar 2025
FMR LLC
13F
Company
0%
225
$1,127 31 Mar 2025
13F
SBI Securities Co., Ltd.
13F
Company
0%
188
$942 31 Mar 2025
13F
Activest Wealth Management
13F
Company
0%
120
$601 31 Mar 2025
13F
BlackRock, Inc.
13F
Company
0%
30
$150 31 Mar 2025
13F
BANK OF AMERICA CORP /DE/
13F
Company
0%
10
$50 31 Mar 2025
13F
GROUP ONE TRADING LLC
13F
Company
0%
9
$45 31 Mar 2025
13F
Richard Alan Burch
3/4/5
Director
class O/S missing
2,917
26 Feb 2024
Abel de la Rosa
3/4/5
Director
class O/S missing
2,362
27 Jun 2025
David R. Keefer
3/4/5
Director
class O/S missing
2,362
27 Jun 2025
John C. Thomas
3/4/5
Director
class O/S missing
2,362
27 Jun 2025
Richard James Whitley
3/4/5
Director
class O/S missing
2,362
27 Jun 2025

Institutional Holders of Dogwood Therapeutics, Inc. - Common Stock, $0.0001 par value (DWTX) as of Q2 2025

As of 30 Jun 2025, Dogwood Therapeutics, Inc. - Common Stock, $0.0001 par value (DWTX) was held by 10 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 43,200 shares. The largest 10 holders included MORGAN STANLEY, GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, Tower Research Capital LLC (TRC), SBI Securities Co., Ltd., Activest Wealth Management, BlackRock, Inc., RAYMOND JAMES FINANCIAL INC, BANK OF AMERICA CORP /DE/, and GROUP ONE TRADING LLC. This page lists 10 institutional shareholders reporting positions in this security for the Q2 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders
13
Q2 2025 holders
10
Holder diff
-3
Investor Q1 2025 Shares Q2 2025 Shares Share Diff Share Chg % Q1 2025 Value $ Q2 2025 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .